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In some patients with congestive heart failure, left ventricular (LV) systolic dysfunction improves, which is accompanied by 
improvements in both clinical symptoms and hemodynamics (1-7). 
Some cases of idiopathic dilated cardiomyopathy (IDCMP) and 
tachycardia- induced cardiomyopathy (TIC) are examples that 
show improvement of LV systolic function (8-11). Congestive 
heart failure caused by systemic metabolic factors, such as sepsis, 
hypocalcemia, hypothyroidism, pheochromocytoma and peripar-
tum cardiomyopathy, is another example. Improvement of LV sys-
tolic function may also be observed after treatment with interferon 
and amphotericin B (12-17).
However, neither the clinical course of the nonischemic left 
heart failure nor clinical guidelines on the management of patients 
who recover from left heart failure have been established. In the 
present study, the clinical progress of patients who recovered from 
congestive heart failure caused by nonischemic LV systolic dysfunc-
tion was investigated.
Methods
Patients with congestive heart failure accompanied by LV systolic dys-
function were selected retrospectively. Only patients whose symptoms 
were relieved by medication during the past 13 years were included in 
the study. Patients were monitored by echocardiography after recovered 
LV systolic dysfunction was confirmed by echocardiography. Patients 
with myocardial failure caused by coronary artery disease, hypertension, 
acute myocarditis, stress-induced cardiomyopathies, and cardiomyopa-
thies accompanied by metabolic diseases or endocrine disorders were 
excluded. 
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BaCKGRouNd: Some patients with nonischemic left ventricular (LV) 
systolic failure recover to have normal LV systolic function. However, few 
studies on the rates of recovery and recurrence have been reported, and no 
definitive indicators that can predict the recurrence of LV dysfunction in 
recovered idiopathic dilated cardiomyopathy (IDCMP) patients have been 
determined. It was hypothesized that patients who recovered from nonis-
chemic LV dysfunction have a substantial risk for recurrent heart failure. 
Methods: Forty-two patients (32 men) with IDCMP (mean [± SD] age 
56.9±8.7 years) who recovered from systolic heart failure (LV ejection frac-
tion [LVEF] of 26.5±6.9% at initial presentation) to a near-normal state 
(LVEF of 40% or greater, and a 10% increase or greater in absolute value) 
were monitored for recurrence of LV systolic dysfunction. Patients with sig-
nificant coronary artery disease were excluded. Patients were monitored for 
41.0±26.3 months after recovery (LVEF 53.4±7.6%) from LV dysfunction.
Results: LV systolic dysfunction reappeared (LVEF 27.5±8.1%) during 
the follow-up period in eight of 42 patients (19.0%). No significant differ-
ence between the groups with or without recurrent heart failure was 
observed in the baseline clinical and echocardiographic characteristics. 
However, more patients in the recurred IDCMP group than those in the 
group that maintained the recovery state had discontinued antiheart fail-
ure medication (62.5% versus 5.9%, P<0.05). 
CoNClusioNs: LV dysfunction recurs in some patients with revers-
ible IDCMP. The recurrence was significantly correlated with the discon-
tinuation of antiheart failure drugs. The results suggest that continuous 
medical therapy may be mandatory in patients who recover from LV sys-
tolic dysfunction.
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la récupération et la récurrence de la dysfonction 
systolique ventriculaire chez les patients atteints 
d’une myocardiopathie dilatée idiopathique
histoRiQue : Certains patients atteints d’une insuffisance systolique 
ventriculaire gauche (VG) non ischémique récupèrent et retrouvent une 
fonction systolique VG normale. Cependant, il existe peu d’études sur les 
taux de récupération et de récurrence, et on n’a déterminé aucun indicateur 
définitif pour prévenir une récurrence de la dysfonction VG chez des patients 
qui se sont remis d’une myocardiopathie dilatée idiopathique (MCDI). Il a 
été postulé que les patients qui ont récupéré d’une dysfonction VG non 
ischémique courent un risque important d’insuffisance cardiaque récurrente.
MÉthodoloGie : Quarante-deux patients (32 hommes) ayant une 
MCDI (âge moyen [±ÉT] de 56,9±8,7 ans) qui ont récupéré d’une 
insuffisance cardiaque systolique (fraction d’éjection VG [FÉVG] de 
26,5±6,9 % à la présentation initiale) jusqu’à retrouver un état quasi-
normal (FÉVG supérieure à au moins 40 % et augmentation d’au moins 10 % 
en valeur absolue) ont été suivis afin de surveiller toute récurrence de la 
dysfonction systolique VG. Les patients atteints d’une coronaropathie 
importante ont été exclus. Les patients ont été suivis pendant 41,0±26,3 mois 
après avoir récupéré (FÉVG de 53,4±7,6 %) de la dysfonction VG.
RÉsultats : La dysfonction systolique VG a refait son apparition (FÉVG 
27,5±8,1 %) pendant la période de suivi chez huit des 42 patients (19,0 %). 
On n’a observé aucune différence significative entre les groupes avec ou sans 
insuffisance cardiaque récurrente dans les caractéristiques cliniques et 
échocardiographiques de départ. Cependant, plus de patients du groupe 
ayant eu une récurrence de la MCDI que de celui ayant maintenu leur état 
de récupération avaient arrêté de prendre leurs médicaments contre 
l’insuffisance cardiaque (62,5 % par rapport à 5,9 %, P<0,05).
CoNClusioNs : La dysfonction VG récidive chez certains patients 
présentant une MCDI réversible. La récurrence était corrélée de manière 
significative avec l’arrêt des médicaments contre l’insuffisance cardiaque. 
Selon les résultats, une médicothérapie continue pourrait être impérative 
chez les patients qui se rétablissent d’une dysfonction systolique VG.
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Forty-two patients with reversible nonischemic LV systolic failure 
were enrolled. Patients had undergone clinical follow-up and echocar-
diography at Severance Hospital (Seoul, Republic of Korea) during 
the past 13 years (since 1995). Originally, there were 86 patients with 
reversible nonischemic LV systolic failure who met the enrolment cri-
teria of the present study. However, 44 patients were excluded because 
they had not been followed up, had died without leaving behind any 
medical records or could not be contacted. 
The following information was confirmed by chart review: the 
onset of the first symptoms; symptoms and findings when congestive 
heart failure was diagnosed; initial echocardiography findings that 
showed LV systolic dysfunction and other findings observed by elec-
trocardiography, x-ray and coronary angiography; etiology of dilated 
cardiomyopathy (DCMP); echocardiographic findings once LV func-
tion had recovered after proper medical treatment; and clinical data 
that included evaluation of symptoms and echocardiographic find-
ings at the time of subsequent follow-up visits. 
LV systolic dysfunction was defined as an ejection fraction (EF) of 
less than 40% by echocardiography. The recovery of LV systolic func-
tion was defined as recovery of the EF to a level of 40% or greater and 
a net increase in EF of 10% or greater. 
statistical data
All values in the present study are presented as mean ± SD. Statistical 
data were processed by SPSS (Windows Release 13.0; SPSS Inc, USA) 
and considered to be statistically significant when P<0.05. The 
unpaired t test and χ2 test were used to compare variables between the 
groups. The dichotomizing logistic regression procedure and the 
Kaplan-Meier test were used to analyze factors that significantly 
affected the prognosis of the groups. 
Results
Patient characteristics 
Thirty-two men (76%) and 10 women (24%) with a mean age of 
56.9±8.7 years were reviewed. Thirty-three patients (79%) were New 
York Heart Association class III and nine patients (21%) were class IV 
when they were diagnosed with congestive heart failure. 
LV systolic dysfunction (LVEF less than 40%) was confirmed in all 
patients by echocardiography (mean EF 26.5±6.9%). All of the patients 
were treated with angiotensin-converting enzyme inhibitors or angio-
tensin receptor antagonists. Beta-blockers were added to the regimen in 
20 patients (48%). All patients showed improved symptoms and LV 
contractile function after treatment. The EF at the time of improvement 
was 53.4±7.6% (determined by echocardiography) and the net increase 
was 24.7±8.7% from the initial value. The mean time to show improved 
symptoms and echocardiographic findings was 15.4±11.8 months. 
Patients were monitored for 41.0±26.3 months after improvement was 
confirmed, meaning that they were followed up for 48.4±15.3 months 
from the time of their initial diagnosis of heart failure (Table 1).
Progress after clinical improvement and reversible recovery
Recovery from congestive heart failure and LV contractile dysfunction 
was maintained in 34 patients (80.9%) with a mean EF of 53.9±8.0%. 
The improved states were maintained for 32.3±13.9 months. However, 
LV systolic dysfunction recurred in eight patients (19.0%) whose mean 
EF was 27.5±8.1%. The recurrence occurred 44.9±33.6 months after 
recovery (Table 2).
intergroup comparison
The clinical characteristics of the groups with or without recurrent heart 
failure are compared in Table 3. Maintenance of antiheart failure 
Table 1
Clinical characteristics of patients
Number of patients 42




Initial New York Heart Association class, n (%)
III 33 (79)
IV 9 (21)
Initial EF, %, mean ± SD 26.5±6.9
Prescribed antiheart failure medication, n (%)
ACE inhibitors or ARBs, no beta-blockers 22 (52)
ACE inhibitors or ARBs, plus beta-blockers 20 (48)
Time to recovery of EF, months, mean ± SD 15.4±11.8
EF at the time of recovery, %, mean ± SD 53.4±7.6
ACE Angiotensin-converting enzyme; ARB Angiotensin II receptor blocker; EF 
Ejection fraction
Table 2





















M 47 34 18 61 37 21
F 56 33 12 49 11 31
M 38 24 8 47 46 21
M 76 39 25 58 69 38
F 56 26 12 41 46 21
M 36 28 21 51 21 31
M 64 27 1 41 96 29
F 63 20 4 47 33 28
EF Ejection fraction; F Female; M Male
Table 3
Clinical and echocardiographic characteristics in patient 











Men:Women, n 3.89:1 1.67:1 0.570
Age, years 56.4±13.0 51.2±12.7 0.754
Initial NYHA class 3.2±0.3 3.2±0.4 0.369
Initial Framingham score 4.7±1.6 4.6±1.1 0.803
Patient with initial MR (≥ grade 2), n (%) 19 (46.3) 2 (22.2) 0.131
Initial EF, % 27.5±7.3 24.8±6.8 0.109
Initial LVEDD, mm 62.7±6.8 65.0±8.7 0.734
Initial LVESD, mm 53.0±7.8 54.6±7.6 0.369
EF improvement, ∆% 23.5±9.7 25.6±6.2 0.531
EF after recovery, % 53.9±8.0 47.5±6.8 0.301
LVEDD after recovery, mm 51.3±4.9 58.5±9.9 0.388
LVEDD improvement, ∆% 12.7±4.7 11.6±5.5 0.263
LVESD after recovery, mm 36.4±4.8 47.5±11.3 0.066
LVESD improvement, ∆% 29.3±8.1 16.7±7.8 0.057
Time to recovery, months 16.2±14.2 14.7±9.3 0.523
Patient who stopped antiheart failure 
medication after recovery, n (%)
2 (5.9) 5 (62.5) 0.020*
Patient prescribed beta-blocker, n (%) 21 (67.7) 2 (25) 0.114
Values are presented as mean ± SD unless stated otherwise. *P<0.05 indi-
cates significance. ∆% Percentage change; EF Ejection fraction; LVEDD Left 
ventricular end-diastolic dimension; LVESD Left ventricular end-systolic 
dimension; MR Mitral regurgitation; NYHA New York Heart Association
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medication after recovery was the only parameter that was significantly 
different between the groups. Among patients who developed recur-
rence of left heart failure, three patients discontinued their medications 
as recommended by their physician and two patients on their own 
accord. Heart failure relapsed 32.2±7.6 months after they discontinued 
the medication. In the group without recurrence, two patients discon-
tinued their medications as recommended by their physician and no 
evidence of recurrence was detected at nine and 72 months after discon-
tinuation. Maintenance of the medication was proven to be a significant 
factor in a multiple regression analysis that compared risk factors such as 
sex, age, severity of heart failure symptoms at the time of diagnosis, EF, 
time to recovery and antiheart failure medication (P<0.05) (Table 4). 
The groups with or without maintenance of medication after recovery 
were compared (Figure 1), and the group with maintained medication 
had significantly fewer recurrences (P=0.021). 
disCussioN
When following congestive heart failure patients with LV systolic 
dysfunction, it has often been observed that some patients recover and 
develop normal LV systolic function (9,10). This phenomenon is lim-
ited not only to ischemic heart diseases and myocarditis, but also to 
IDCMP, DCMPs secondary to certain drugs and alcohol abuse, TIC 
and peripartum cardiomyopathies. However, few studies on recovery 
rates have been reported, and the indicators that predict the possibility 
of recovery in DCMP patients have not been identified. 
Some patients with IDCMP develop recurrence of LV systolic 
failure after recovery. In a recent study of 24 TIC patients, Nerheim 
et al (11) reported that patients showed improvement in both symp-
toms and LV function 5.8±4.8 months after tachycardia was con-
trolled by medical therapy or electrocatheter ablation. However, in 
five patients, LV dysfunction rapidly reappeared when tachycardia 
redeveloped. The authors suggested that the hearts of patients with 
TIC might develop ultrastructural changes that make the heart more 
vulnerable to recurrent heart failure, even though symptoms and LV 
function have improved. In fact, they observed degenerative changes 
such as interstitial fibrosis and edema in two patients with TIC on 
endomyocardial biopsy. Ultrastructural changes have also been 
proven in animal experiments. Katstura et al (18) induced TIC in 
canines and observed fibrosis of cardiac muscle without changes in 
heart weight, which suggested that the heart did not have macro-
scopic changes such as cardiomegaly. Takahashi et al (19) reported 
an increase of beta-actin, gamma-actin and alpha-tubulin in animal 
models of TIC. These results suggested that LV systolic function 
alone may not be sufficient as a surrogate marker of remodeling and 
clinical improvement from congestive heart failure. In addition, 
improved LV contractile function evaluated by echocardiography 
cannot be used as an indicator of recovery from TIC (20).
Improvement in congestive heart failure symptoms and recovery 
from LV systolic dysfunction evaluated by echocardiography cannot be 
regarded as a complete recovery from IDCMP. We assumed that a his-
tory of congestive heart failure itself could be a risk factor for recurrent 
heart failure and hypothesized that ultrastructural changes of cardiac 
muscle were associated. In fact, two patients in the present study were 
subjected to endomyocardial biopsy, and ultrastructural changes 
including interstitial fibrosis were detected. These findings were not 
observed in all patients, but they could affect vulnerability to stimuli, 
result in reduced cardiac contractility, and be a risk factor for recurrent 
heart failure. Additional studies are needed to prove this hypothesis.
Few studies have been conducted on whether IDCMP patients 
who recovered from congestive heart failure can maintain improve-
ment in the long term or whether LV dysfunction will recur. Because 
we often find that DCMP patients do recover, it may be very impor-
tant to understand their clinical progress. In the present study, we 
confirmed that patients who recovered from LV failure developed 
recurrent congestive heart failure associated with LV contractile 
dysfunction, sometimes without any clinically specific reason. 
Therefore, patients should be continuously monitored in follow-up 
studies, even after left heart failure recovery. In the recurrent group, 
recurrence of LV contractile dysfunction was observed 
44.9±33.6 months after recovery from heart failure. The group whose 
recovery state was maintained did not show a recurrence of heart 
failure for a follow-up period of 32.3±13.9 months. The follow-up 
period for this group was relatively short, so we cannot exclude the 
possibility of subsequent recurrence.
Other questions that should be raised in the management of recov-
ered LV systolic failure are the type and duration of therapy. The 
Figure 1) Recurrence of heart failure (Kaplan-Meier curve). a Patients 
who maintained their antiheart failure medication. B Patients who discontin-
ued their antiheart failure medication
Table 4
Factors that influence recurrent left ventricular systolic 
dysfunction




Causative disease 4.461 0.344
New York Heart Association class 0.917 0.364
Framingham score 0.749 0.309
Ejection fraction 0.861 0.212
LVEDD 1.113 0.168
LVESD 1.009 0.126
Mitral regurgitation (≥ grade 2) 0.063 0.126
Concomitant beta-blocker usage 0.361 0.407
Time to recovery 0.861 0.434
After recovery
Ejection fraction 0.749 0.401
LVEDD 1.313 0.826
LVESD 0.695 0.146





*P<0.05 indicates significance. LVEDD Left ventricular end-diastolic dimen-
sion; LVESD Left ventricular end-systolic dimension
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established protocols of medical therapy for congestive heart failure are 
suitable for typical chronic heart failure with decreasing heart function, 
but may not be useful in cases in which heart failure recovers after treat-
ment. However, a decision is needed regarding whether medical therapy 
should be continued. The current study showed that the recurrence rate 
of left heart failure was significantly correlated with the discontinuation 
of antiheart failure drugs, which suggests that continuous medical ther-
apy in recovered IDCMP patients is indicated. Although many studies 
showed that beta-blockers, angiotensin-converting enzyme inhibitors 
and angiotensin receptor antagonists were effective in treating conges-
tive heart failure, it is controversial whether the drugs should be admin-
istered to patients after recovery of LV dysfunction despite the high cost 
and adverse effects. More studies are needed on this matter. 
The present study has the following limitations: it was performed 
retrospectively; analyses of biochemical markers, including genetic 
factors or cytokines, were not included; data from many patients who 
dropped out during the follow-up period could not be collected, 
which could have introduced a sampling error; the number of sub-
jects was small; and diastolic function was not included as an 
echocardiographic parameter. Moreover, the study was initiated 
before clear criteria for the recovery of heart failure were established. 
Nevertheless, the present study clearly shows that LV systolic dys-
function can relapse in patients who have recovered from left heart 
failure. Our data suggest that the discontinuation of antiheart failure 
drugs after recovery from heart failure is an independent risk factor 
for recurrence of systolic dysfunction. Continuous follow-up and 
proper medical therapy should be considered for patients with nonis-
chemic left heart failure. In future studies, genetic analyses, correla-
tion with biochemical markers and responses to various drugs should 
be determined.
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